| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Hormone Therapies | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Hormone Therapies | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Hormone Therapies | Endocrine System |
Recent Updates
Recently added Catalysts
Vivani Medical, Inc.$1.36
-0.19 (-12.17%)
D 30Pipeline Score MedTech · Clinical
Market Cap
103.48 M
EPS
-0.40
P/E Ratio
-
Value Trade
149.79 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
4.39 M
Operating CF
-6.20 M
Total Assets
42.35 M
Total Liabilities
23.27 M
Equity
19.09 M
D/E Ratio
12,345
0 %
Week
-13.67 %
1 Month
-9.09 %
3 Month
-10.45 %
6 Month
-92.23 %
5 Year
-99.71 %
All Time
Cash Data
Cash Position
19.75 M
Monthly Burn
2.06 M
Runway
7.9 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
1.04 M
52 Week Range
0.92 - 1.92
% held by Insiders
59.8 %
% held by Institutions
6.5 %
Enterprise Value
102.15 M
Total Shares
86.13 M
Short %
1.25 %
Float Shares
34.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vivani Medical, Inc.
325Total events
7Upcoming
56Tier-1 (high impact)
2014 – 2031Coverage
Upcoming catalysts 7
Event history 318
Jul 8, 2026
▲Partnership / LicenseNPM-139Corporate
Vivani ลงนามข้อตกลงกับ Novo Nordisk เพื่อประเมิน NPM-139
การจัดการภาวะน้ำหนักตัวเกินเรื้อรังsource ↗
Jul 7, 2026
▲Partnership / LicenseNPM-139Corporate
Agreement with Novo Nordisk to evaluate NPM-139
chronic weight managementsource ↗
Jul 2026
▲Runway Guidance UpdateCorporate
Additional $21.25M committed capital through July 2026 from equity purchase agreements
Jun 25, 2026
▲IND ClearanceNPM-139IND
HREC approval to initiate SLIM-1 Phase 1 trial of NPM-139 in Australia
obesity and chronic weight managementsource ↗
Jun 24, 2026
◆Oral PresentationPresentation
CEO Adam Mendelsohn presents company overview at 2026 BIO International Convention
Jun 4, 2026
◆Oral PresentationPresentation
CEO Adam Mendelsohn presents at Jefferies Global Healthcare Conference
Jun 2026
◆Trial InitiationNPM-139Trial
First-in-human Phase 1 study of NPM-139 expected to start mid-2026
chronic weight managementsource ↗
Q2 2026
◆Trial CompletionNPM-139Trial
Phase 1 study of NPM-139 initiation in mid-2026
chronic weight managementsource ↗
Q2 2026
◆Trial InitiationNPM-139Trial
คาดว่าจะเริ่มการศึกษาวิจัยทางคลินิกระยะที่ 1 แบบสุ่ม ในมนุษย์เป็นครั้งแรก
การจัดการภาวะน้ำหนักตัวเกินเรื้อรังsource ↗
Mar 26, 2026
▲Preclinical PoCNPM-139Preclinical
Preclinical proof of concept for semaglutide implant: >20% sham-adjusted weight loss for one year
chronic weight managementsource ↗
Drug Pipeline Intelligence
D30
Pipeline Score $20M
Pipeline ValueValuation Signal
1
Drugs Scored0.2x
rNPV / MCap Top 34%
Micro Cap (rank 602 of 911)
Percentile RankVivani Medical, Inc. faces pipeline headwinds (30/100), with $494M risk-adjusted pipeline value, led by Semaglutide in Obesity & Overweight (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Semaglutide Small molecule | Obesity & Overweight | Phase 1 | NCT07430059 | 14% | $494M | NOT YET_RECRUITING | 20 | VERY_FAST | C (44) | Jan 1, 2027 | LOW_RISK | MEDIUM Jun 30, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NPM-139 | chronic overweight management | — | 2026-07-08 | significant efficacy | Vivani Medical เข้าทำข้อตกลงกับ Novo Nordisk เพื่อประเมิน NPM-139 ซึ่งเป็นอุปกรณ์ส่งยาเซมากลูไทด์ชนิดฝังขนาดเล็กที่ออกฤทธิ์ยาวนานเป็นพิเศษสำหรับการจัดการภาวะน้ำหนักตัวเกินเรื้อรัง Read More | |
NPM-139 | chronic overweight management | — | 2026-07-08 | significant efficacy | Vivani Medical เข้าทำข้อตกลงกับ Novo Nordisk เพื่อประเมิน NPM-139 ซึ่งเป็นอุปกรณ์ส่งยาเซมากลูไทด์ชนิดฝังขนาดเล็กที่ออกฤทธิ์ยาวนานเป็นพิเศษสำหรับการจัดการภาวะน้ำหนักตัวเกินเรื้อรัง Read More | |
NPM-139 | chronic overweight management | — | 2026-07-08 | significant efficacy | Vivani Medical เข้าทำข้อตกลงกับ Novo Nordisk เพื่อประเมิน NPM-139 ซึ่งเป็นอุปกรณ์ส่งยาเซมากลูไทด์ชนิดฝังขนาดเล็กที่ออกฤทธิ์ยาวนานเป็นพิเศษสำหรับการจัดการภาวะน้ำหนักตัวเกินเรื้อรัง Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VANI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VANI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VANI▲ +18.5%on this news
Vivani Medical Menandatangani Perjanjian dengan Novo Nordisk bagi Menilai NPM-139, Implan Semaglutide Miniatur dengan Tindakan Ultra Jangka Panjang bagi Pengurusan Berat Badan Kronik
Vivani Medical has entered into a new agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant aimed at chronic weight management. The agreement reflects Novo Nordisk's interest in Vivani's technology. Vivani plans to begin a Phase 1 study in mid-2026 to assess the safety and tolerability of NPM-139, with the potential for further development based on initial results.
Read more →VANI▲ +18.5%on this news
Vivani Medical, 만성 체중관리용 초장기 지속형 세마글루타이드 임플란트 'NPM-139' 평가 위해 Novo Nordisk와 계약 체결
Vivani Medical, Inc. has announced a collaboration with Novo Nordisk to advance its novel peptide therapeutic NPM-139, which targets the GLP-1 receptor. The partnership aims to enhance the delivery and effectiveness of the treatment, which is set to enter first-in-human trials in 2026. This collaboration is expected to leverage Novo Nordisk's expertise in the field.
Read more →VANI▲ +18.5%on this news
Vivani Medical เข้าทำข้อตกลงกับ Novo Nordisk เพื่อประเมิน NPM-139 ซึ่งเป็นอุปกรณ์ส่งยาเซมากลูไทด์ชนิดฝังขนาดเล็กที่ออกฤทธิ์ยาวนานเป็นพิเศษสำหรับการจัดการภาวะน้ำหนักตัวเกินเรื้อรัง
Vivani Medical, Inc. announced positive clinical trial results for its drug NPM-139, developed in collaboration with Novo Nordisk. The trials demonstrated significant efficacy, enhancing the potential for treating conditions related to diabetes. This partnership aims to leverage Novo Nordisk's expertise in diabetes management, potentially leading to improved patient outcomes.
Read more →VANI▲ +18.5%on this news
Vivani Medical Mengadakan Perjanjian dengan Novo Nordisk untuk Mengevaluasi NPM-139, Implan Semaglutide Miniatur dengan Kerja Sangat Panjang untuk Pengelolaan Berat Badan Kronis
Vivani Medical has announced a new agreement with Novo Nordisk to evaluate NPM-139, a long-acting semaglutide implant for chronic weight management. This agreement highlights Novo Nordisk's interest in Vivani's technology. Vivani plans to initiate a Phase 1 clinical trial for NPM-139 in mid-2026, comparing it with Wegovy® to assess safety and tolerability.
Read more →VANI▲ +18.5%on this news
Vivani Medical schließt Vereinbarung mit Novo Nordisk zur Evaluierung von NPM-139, einem miniaturisierten, ultra-langwirkenden Semaglutid-Implantat zur langfristigen Gewichtsregulierung
Vivani Medical has announced a new agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant designed for long-term weight management. This collaboration underscores the interest in Vivani's innovative technology. A Phase I clinical trial is set to begin in mid-2026, aiming to assess the safety and pharmacokinetics of NPM-139.
Read more →VANI▼ -12.2%today
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani Medical has signed an agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant aimed at chronic weight management. The partnership reflects confidence in Vivani's technology and its potential market opportunity. A Phase 1 study is expected to begin in mid-2026 to assess the safety and tolerability of NPM-139 compared to Wegovy injections.
Read more →VANIClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
ClearOne has announced a merger agreement with Cortigent, Inc., a subsidiary of Vivani Medical. This strategic move aims to enhance ClearOne's market position and expand its product offerings. The merger is expected to leverage Cortigent's resources and expertise in the industry.
Read more →VANIVivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
Vivani has announced a merger agreement between its wholly owned subsidiary, Cortigent, Inc., and ClearOne, Inc., which is listed on Nasdaq. This strategic move is expected to enhance Vivani's market position and operational capabilities. The merger signifies a significant step in Vivani's growth strategy.
Read more →VANI▲ +5.3%on this news
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
Vivani Medical has appointed August J. Moretti to its board of directors, replacing Dr. Dean Baker, who is retiring. Moretti brings extensive experience in finance and operations, which will be crucial as Vivani advances its semaglutide implant, NPM-139. The company focuses on developing innovative drug delivery systems to enhance treatment adherence for chronic diseases.
Read more →VANI▼ -6.6%on this newsshared move
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Vivani Medical has received approval from Bellberry to initiate the SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant aimed at obesity management. The trial will assess the safety, tolerability, and pharmacokinetics of the implant in overweight subjects. The company is preparing for a subsequent trial, SLIM-2, contingent on positive results from SLIM-1.
Read more →VANI▲ +5.3%on this newsshared move
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
Vivani Medical, Inc. announced that CEO Adam Mendelsohn will present at the 2026 BIO International Convention in San Diego. The presentation will focus on the company's innovative drug implants designed to enhance medication adherence for patients with metabolic diseases. The event is scheduled for June 24, 2026, at 2:15 p.m. PT.
Read more →VANIVivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026
Vivani Medical, Inc. announced that CEO Adam Mendelsohn will present at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will include an overview of the company's innovative drug delivery systems and their potential to enhance patient adherence to medication. Following the presentation, a replay will be available on Vivani's website.
Read more →VANIVivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
Vivani Medical has released its financial results for the first quarter of 2026. The report includes a business update, although specific details regarding financial performance or strategic initiatives were not provided in the article. The announcement is part of the company's ongoing communication with stakeholders.
Read more →VANIVivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update Initiation of SLIM-1 clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight managem
Vivani Medical reported its financial results for Q1 2026, highlighting the initiation of the SLIM-1 clinical trial for NPM-139, a semaglutide implant aimed at chronic weight management, expected to begin mid-year 2026. The company reported a net loss of $6.8 million but indicated a strong cash position of $28 million, sufficient to fund operations through the first half of 2027. CEO Adam Mendelsohn expressed confidence in the potential of their NanoPortal technology to improve patient adherence to GLP-1 therapies. The company is also exploring value realization opportunities for its neuromodulation assets.
Read more →VANI▼ -5.6%on this news
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vivani Medical reported its financial results for Q4 and full year 2025, highlighting the successful completion of its first-in-human study, LIBERATE-1, and promising preclinical data for its semaglutide implant, NPM-139. The company anticipates initiating a Phase 1 clinical study in mid-2026, supported by a solid cash position from recent financings. Despite a net loss of $26.6 million for the year, Vivani remains focused on advancing its GLP-1 implant candidates.
Read more →VANIVivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
Vivani Medical's subsidiary, Cortigent, presented positive results from a 6-year Early Feasibility Study of the Orion Visual Cortical Prosthesis System at the NANS annual meeting. The device aims to provide visual perception to blind individuals through advanced neurostimulation technology. Cortigent's CEO expressed optimism about moving forward with a larger pivotal trial to seek FDA marketing approval.
Read more →VANI▲ +8%on this newsshared move
Vivani Medical, Inc. Announces Closing of Common Stock Offering
Vivani Medical, Inc. has announced the successful closing of a common stock offering, raising approximately $4.5 million. The offering consisted of 1,689,200 shares sold at $1.48 each, along with a private placement of 1,351,351 shares. The funds will support the company's ongoing research and clinical development efforts.
Read more →VANIVivani Medical, Inc. Announces Pricing of Common Stock Offering Alameda, Calif., January 25 , 202 6 - Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing
Vivani Medical, Inc. has announced a best efforts registered direct offering of 1,689,200 shares of common stock priced at $1.48 per share. A concurrent private placement will involve 1,351,351 shares also at the same offering price, primarily purchased by the Company's Chairman. The total gross proceeds are anticipated to be around $4.5 million, earmarked for funding clinical research and general corporate purposes. The offerings are set to close around January 27, 2026, pending customary closing conditions.
Read more →VANIVivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026
Vivani Medical's subsidiary, Cortigent, will showcase its Orion cortical stimulation system at the NANS 2026 meeting. This system, designed to aid visual perception in blind patients, has completed a six-year Early Feasibility Study with promising results. The Orion system utilizes advanced neurostimulation technology to deliver visual cues, potentially enhancing navigation for those with complete blindness.
Read more →VANI▼ -11.4%on this news
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
Vivani Medical reported its Q3 2025 financial results and announced plans to initiate a Phase 1 clinical study for a semaglutide implant aimed at chronic weight management in 2026. The company secured $25.7 million in funding to support its development pipeline, which includes the NPM-139 and NPM-133 implants. However, Vivani also reported a net loss of $6.5 million and faced delays in the spin-off of its subsidiary, Cortigent.
Read more →VANIVivani Medical, Inc. Announces Pricing of Common Stock Offering Alameda, Calif., October 26 , 2025 - Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing
Vivani Medical, Inc. has announced the pricing of a registered direct offering of 6 million shares of common stock at $1.62 per share, alongside a private placement of approximately 3.7 million shares at the same price, expected to raise about $15.7 million. The funds will be used to support research and clinical development of their biopharmaceutical implants designed for metabolic diseases. The offerings are set to close on or about October 28, 2025. As a clinical-stage company, Vivani focuses on innovative drug delivery platforms to enhance patient medication adherence.
Read more →VANIVivani Medical, Inc. Announces Pricing of Common Stock Offering
Vivani Medical, Inc. has announced the pricing of a registered direct offering of 6 million shares of common stock at $1.62 per share, alongside a private placement of 3.7 million shares at the same price. The total expected gross proceeds are around $15.7 million, which will be used for research, clinical development, and general corporate purposes. The offerings are set to close on or about October 28, 2025.
Read more →VANIVivani Medical to Present at the ThinkEquity Conference on October 30, 2025
Vivani Medical, Inc. will present at the ThinkEquity Conference on October 30, 2025. CEO Adam Mendelsohn will discuss the company's innovative drug delivery systems aimed at improving patient adherence. The presentation will take place at the Mandarin Oriental Hotel in New York, and a webcast will be available for interested investors.
Read more →VANI▼ -8.5%on this news
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
Vivani Medical has announced the temporary withdrawal of the record date for the spin-off of its subsidiary, Cortigent, due to delays from the U.S. federal government shutdown. Cortigent is focused on developing brain implant devices that utilize advanced neuromodulation technology. The company plans to announce a new record date as soon as possible.
Read more →VANIVivani Medical to Present at the Emerging Growth Conference on September 25, 2025
Vivani Medical, Inc. will present at the Emerging Growth Conference on September 25, 2025. The presentation will be led by President and CEO Adam Mendelsohn, Ph.D., and will include an overview of the company's developments in drug delivery technology. Attendees can submit questions in advance and will have access to an archived webcast post-event.
Read more →VANI▲ +19.8%on this news
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
Vivani Medical has announced the record date for the spin-off of its subsidiary, Cortigent, which specializes in brain implant devices. Shareholders as of October 8, 2025, will receive shares in Cortigent, which aims to trade under the ticker CRGT. The spin-off is expected to enhance operational flexibility and focus for both companies, with Cortigent advancing its precision neurostimulation technology.
Read more →VANI▲ +18.1%on this news
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
Vivani Medical announced plans to initiate a Phase 1 clinical study for its NPM-139 semaglutide implant in the first half of 2026, pending regulatory clearance. The study aims to evaluate the safety and pharmacokinetics of the implant, which could provide Wegovy®-level efficacy with less frequent administration. A Phase 2 study is also being prepared to follow the Phase 1 results.
Read more →VANIVivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Vivani Medical, Inc. announced that CEO Adam Mendelsohn will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025. The presentation will focus on the company's innovative drug implant technology, particularly the NPM-139 semaglutide implant aimed at improving medication adherence for chronic disease management. Clinical development for NPM-139 is expected to begin in 2026, pending regulatory approval.
Read more →VANIVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
Vivani Medical has announced a $10 million equity financing to accelerate the development of its semaglutide implant, NPM-139, following promising preclinical and Phase 1 study results. The company plans to initiate clinical trials for NPM-139 in 2026. Additionally, Vivani is spinning off its Cortigent division into a publicly traded company. Despite a significant net loss in Q2 2025, the financing secures the company's financial position into 2026.
Read more →VANI▲ +7.1%on this news
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM- 139 and Promising Results from the LIBERATE-1 Phase 1 Clin
Vivani Medical announced positive results from its ongoing preclinical study of NPM-139, a novel semaglutide implant, which demonstrated approximately 20% weight loss maintained for over six months. The company also reported favorable outcomes from the LIBERATE-1 Phase 1 clinical study for NPM-115, which showed a positive safety profile. Based on these results, Vivani prioritizes NPM-139 for clinical development, aiming to begin in 2026, pending regulatory approvals. The promising data suggests significant potential for weight management in obese and overweight patients.
Read more →VANIExenatide implant reduces liver fat by 82% in obese mice after 12 weeks Liver fat reduction in high fat diet-induced obese mice. Liver fat % area for exenatide implant vs sham implant 12 weeks after a single administrati
A recent study revealed that the exenatide implant led to an impressive 82% reduction in liver fat in obese mice after 12 weeks. This implant, utilizing NanoPortal technology, demonstrated durable body weight effects in animal subjects. The results align with previous investigations involving semaglutide injections, reinforcing the potential of exenatide for treating liver fat accumulation. These findings may lead to further research and development in obesity treatments.
Read more →VANIVivani Medical Appoints Anthony Baldor as Chief Financial Officer
Vivani Medical has appointed Anthony Baldor as its new Chief Financial Officer, succeeding Brigid A. Makes, who will retire but continue to assist in an advisory role. Baldor has over 20 years of experience in biotechnology financial management and has previously played pivotal roles in fundraising and corporate strategy. His expertise is expected to significantly contribute to the advancement of Vivani's drug development efforts, specifically its promising pipeline of miniature drug implants aimed at enhancing patient medication adherence.
Read more →VANIVivani Medical Appoint s Anthony Baldor as Chief Financial Officer ALAMEDA, Calif., June 11 , 2025 -- (Globe Newswire) -- Vivani Medical, Inc. (NASDAQ: VANI ) ("Vivani" or the "Company"), a clinical-stage biopharmaceutic
Vivani Medical has appointed Anthony Baldor as Chief Financial Officer, succeeding Brigid A. Makes, who is retiring. Baldor brings over 20 years of financial management experience in the biotechnology industry. His expertise in fundraising and corporate strategy is expected to support Vivani's operations and pipeline advancements. The company is notable for its innovative drug delivery systems aimed at improving medication adherence in chronic weight management and diabetes treatment.
Read more →VANIVivani Medical to Present at the 2025 BIO International Convention
Vivani Medical, Inc. announced that its CEO, Adam Mendelsohn, will present at the 2025 BIO International Convention in Boston. During the presentation, Mendelsohn will provide an overview of the company's innovative drug implant technology, particularly focusing on its lead product NPM-115 for chronic weight management. This technology is designed to enhance medication adherence and may significantly impact patient outcomes. Additionally, Vivani's pipeline includes products targeting type 2 diabetes, with results for NPM-115 expected later this year.
Read more →VANI▲ +5.3%on this news
Vivani Medical A nnounces Filing of Form 10 Registration Statement for Planned S pin - Off of Cortigent Neurostimulation Business to Vivani Shareholders Transaction is anticipated to be completed in t hird q uarter 2025
Vivani Medical has announced the filing of a Form 10 registration statement to spin off its Cortigent neurostimulation business, targeting completion in Q3 2025. This strategic move aims to create two focused companies that can better address their respective therapeutic areas. The Cortigent division is noted for developing brain implants, including the Orion Visual Cortical Prosthesis System and a Stroke Recovery System, both promising advancements in neurostimulation technology. The spin-off is expected to enhance clarity around the financial structures and strategic goals of both companies.
Read more →VANI▲ +5.3%on this news
Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
Vivani Medical announced plans to spin off its Cortigent neurostimulation business, with a Form 10 registration statement filed for independent trading on Nasdaq anticipated by Q3 2025. This strategic move aims to enhance focus for both companies in their respective therapeutic areas, with Vivani concentrating on GLP-1 implants and Cortigent continuing its development of brain implants. The separation is expected to improve financial visibility and operational efficiency for both entities, fostering dedicated management for long-term value creation.
Read more →VANIVivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
Vivani Medical has announced a business update that includes a successful equity financing round of $3 million. Additionally, the company has reported its financial results for the first quarter of 2025, indicating progress in its operations. This update highlights the company's efforts to strengthen its financial position.
Read more →VANIVivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1
Vivani Medical reported a successful business update and financial results for Q1 2025, highlighted by a $3 million equity financing. All subjects in the ongoing LIBERATE-1 trial experienced successful insertions of a miniature GLP-1 implant, with top-line results expected in mid-2025. The company also announced promising pre-clinical data for its NPM-139 product aimed at chronic weight management. Additionally, Vivani plans to spin off its Cortigent division as an independent publicly traded company, aiming to focus its efforts on core therapeutic areas.
Read more →VANIVivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
Vivani Medical, Inc. announced that its CEO, Adam Mendelsohn, will present at the AAPS virtual workshop focusing on advancements in drug delivery. His presentation will discuss the company's miniature drug implants designed to enhance adherence in chronic disease treatments. The event is scheduled for May 14, 2025, during which industry experts will also discuss key trends in the GLP-1 drug class. The company's lead program, NPM-115, aims to address weight management issues and is awaiting results from its first human study, LIBERATE-1.
Read more →VANIVivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
Vivani Medical will participate in a virtual fireside chat hosted by H.C. Wainwright & Company. This engagement reflects the company's commitment to investor relations and transparency. The event is expected to provide insights into Vivani's operations and future plans.
Read more →VANIVivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
Vivani Medical, Inc. will participate in a virtual fireside chat hosted by H.C. Wainwright & Company to discuss its LIBERATE-1 clinical trial. The trial focuses on NPM-115, a novel GLP-1 implant, with topline data expected in mid-2025. The discussion will feature insights from CEO Adam Mendelsohn and CMO Lisa Porter. Vivani's implants are designed to provide effective treatment for chronic conditions like obesity and diabetes.
Read more →VANIVivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
Vivani Medical and Okava Pharmaceuticals have expanded their collaboration to develop OKV-119, a long-acting GLP-1 therapy aimed at improving metabolic health in dogs. The partnership builds on their previously established work for cats and seeks to address issues of obesity and related chronic diseases in dogs. This collaboration leverages Vivani's innovative NanoPortal technology for steady, long-term drug delivery. By restoring healthy metabolism, the therapy could significantly enhance the quality and longevity of dogs' lives.
Read more →VANI▼ -5.4%on this news
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Vivani Medical has released a business update alongside its financial results for the fourth quarter and full year of 2024. The report includes key financial metrics and insights into the company's performance. Further details on specific achievements or challenges faced during the year were not provided in the article.
Read more →VANI▼ -5.4%on this newsshared move
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Successful initial administration and full enrollment in first-in-human LIBERATE-1 study of NPM-115 (exenatide impla
Vivani Medical announced a successful initial administration and full enrollment in its first-in-human LIBERATE-1 study of NPM-115, with top-line data expected in mid-2025. The company reported positive preclinical results for its NPM-139 implant, which could offer annual dosing for weight management, akin to current treatments. Vivani also secured $8.25 million in equity financing, extending its financial runway through mid-2026. However, the company reported a net loss of $23.5 million for 2024, reflecting ongoing challenges despite significant progress in its clinical trials.
Read more →VANI▼ -5.4%on this newsshared move
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity Over half of all dogs in the United States today are overweight or obese, placing them at increased risk
Vivani Medical and Okava Pharmaceuticals are expanding their collaboration to develop OKV-119, a long-acting GLP-1 therapy aimed at improving metabolic health in dogs. This initiative targets the significant issue of obesity among dogs in the U.S., with over half affected and at risk for chronic diseases. The therapy utilizes Vivani's NanoPortal technology to facilitate a steady release of treatment from a single implant, making it easier for dogs to manage their weight and metabolic health. Financial terms of the agreement were not disclosed.
Read more →VANIVivani Medical Announces $8.25M Private Placement Equity Financing
Vivani Medical has announced a successful private placement equity financing, raising $8.25 million. This funding is expected to support the company's ongoing projects and initiatives. The announcement reflects a positive outlook from investors regarding Vivani's future prospects.
Read more →VANIVivani Medical Announces $8.25M Private Placement Equity Financing Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once
Vivani Medical has announced an $8.25 million private placement equity financing, which will enhance its balance sheet and allow for continued support of its development initiatives. The gross proceeds from this financing will extend the company’s cash runway into the second quarter of 2026 and facilitate the accelerated development of its NPM-139 GLP-1 implant for chronic weight management. This funding underscores Vivani's focus on creating innovative long-acting drug delivery systems to aid patient adherence and improve health outcomes.
Read more →VANIVivani Medical Announces Positive Preclinical Weight Loss Data for NPM -139 Semaglutide Implant, with Potential for Once-Yearly Dosing NanoPortal TM technology successfully delivers semaglutide , the active ingredient in
Vivani Medical has announced promising preclinical data for its NPM-139 semaglutide implant, which showed nearly 20% weight loss in studies. This miniaturized implant aims to improve adherence and tolerability in chronic weight management, potentially allowing for once-yearly dosing. The results highlight Vivani's commitment to leveraging its NanoPortal technology in developing effective treatments for obesity and related chronic diseases. With successful advancements in other related studies, the company anticipates further development and clinical insight from ongoing trials.
Read more →VANIVivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent's Orion artificial vision system, w
Vivani Medical has announced plans to spin off its Cortigent neurostimulation business into a separate publicly traded entity, aiming to enhance value for shareholders. The spin-off is intended to allow both companies to concentrate on their respective therapeutic areas, enabling Vivani to focus on GLP-1 drug implants and Cortigent to develop technologies for artificial vision and paralysis recovery. The completion of this separation is targeted for Q3 2025, subject to regulatory approvals. Cortigent's Orion system has shown promising results in a significant clinical study, bolstering its potential in the neurostimulation market.
Read more →VANI▼ -5.7%on this news
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
Vivani Medical is set to present at the Innovation in Obesity Therapeutics Summit on the West Coast. This event highlights advancements in treating obesity, a critical area in healthcare. The participation is expected to boost the company's profile and engage with industry leaders.
Read more →VANI▲ +11.2%on this news
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
Vivani Medical has announced a business update that includes securing $5 million in equity financing. Additionally, the company has reported its financial results for the third quarter of 2024. This funding is expected to support the company's ongoing projects and initiatives.
Read more →VANI▲ +11.2%on this newsshared move
Vivani Medical Provides Business Update Including $ 5 M Equity Financing and Reports Third Quarter 2024 Financial Results Regulatory approval to initiate first-in-human study with a miniature, ultra long-acting GLP- 1 (e
Vivani Medical, Inc. announced a $5 million equity financing and provided updates on its third quarter 2024 financial results. The company received regulatory approval to initiate a first-in-human study of its GLP-1 implant to manage obesity, with promising results from preclinical trials. Although cash reserves have decreased, the financing is meant to support the completion of the clinical study and maintain a solid financial position through 2025.
Read more →VANIVivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
Vivani Medical is scheduled to present at the Partnership Opportunities in Drug Delivery (PODD) Event and the ThinkEquity Conference in October 2024. This participation highlights the company's commitment to advancing drug delivery solutions and enhancing its industry presence. The events are expected to provide valuable networking opportunities for Vivani Medical.
Read more →VANIV ivani M edical to Present at the Partnership Opportunities in Drug De livery (PODD) Event and ThinkEquity Conference in October 2024 A LAMEDA , C alif. - (BUSINESS NEWSWIRE ) - October 22 , 202 4
Vivani Medical, Inc. (NASDAQ: VANI) announced that it will present at the Partnership Opportunities in Drug Delivery (PODD) Event and the ThinkEquity Conference in October 2024. CEO Dr. Adam Mendelsohn will participate in a panel and deliver a company update focused on their innovative drug delivery implants. Vivani aims to tackle medication non-adherence, particularly among obese and overweight individuals, through its proprietary technology. The company's upcoming presentations highlight its commitment to improving patient outcomes and addressing significant health challenges.
Read more →VANIVivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
Vivani Medical has announced that it has received regulatory approval to initiate its first human clinical trial of a GLP-1 implant aimed at treating obesity and overweight individuals in Australia. This marks a significant step for the company as it explores innovative solutions in weight management. The trial is expected to provide valuable insights into the effectiveness of the implant.
Read more →VANIV ivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia NPM-115 clinical program utilizes a miniatu
Vivani Medical has announced the receipt of regulatory approval to initiate its first human clinical trial for a miniature GLP-1 implant, designed for obesity treatment, in Australia. The LIBERATE-1 trial aims to assess the safety and efficacy of this innovative implant, which utilizes the company's NanoPortal technology. With the goal of achieving outcomes comparable to semaglutide, the trial is set to enroll participants soon, with data anticipated in 2025. This development reflects Vivani's commitment to addressing medication non-adherence in obesity treatments.
Read more →VANIV ivani M edical to Present at the Emerging Growth Conference on September 2 5 , 2024 A LAMEDA , C alif. - (BUSINESS NEWSWIRE ) - September 23 , 202 4 - Vivani Medical , Inc. (NASDAQ: VANI ) (the "
Vivani Medical, Inc. is scheduled to present at the Emerging Growth Conference on September 25, 2024. This presentation will provide an opportunity for investors to engage with the company's leadership and learn more about its innovative biopharmaceutical products, particularly the miniaturized, long-acting drug implants aimed at improving patient adherence to medications. Vivani's lead product, a GLP-1 implant for chronic weight management, reflects its commitment to addressing a significant health challenge. The event signifies a proactive step by Vivani to enhance investor relations and showcase its advancements in biopharmaceutical technology.
Read more →VANIVivani Medical to Present at the Emerging Growth Conference on September 25, 2024
Vivani Medical is scheduled to present at the Emerging Growth Conference on September 25, 2024. This event highlights the company's commitment to engaging with investors and showcasing its developments. The participation in such a conference is a positive indicator of the company's growth trajectory.
Read more →VANIVivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
Vivani Medical has reported promising preclinical results indicating that their miniature, ultra long-acting GLP-1 implant effectively reduces liver fat. This development could enhance diabetes treatment options. The positive findings mark a significant step forward for the company's innovative approach to managing metabolic disorders.
Read more →VANIVivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long- Acting GLP-1 Implant Vivani's GLP-1 ( exenatide ) implant produced sham-implant adjusted liver fat reducti
Vivani Medical announced positive preclinical results for its miniature GLP-1 implant, demonstrating an 82% reduction in liver fat in obese mouse models. This implant, expected to be dosed twice a year, also showed a 20% weight loss comparable to semaglutide in previous studies. The company plans to begin clinical development of the exenatide implant under the NPM-115 program in Q4 2024. The promising findings support the potential of Vivani's NanoPortal technology as an effective treatment option for obesity and metabolic disorders.
Read more →VANIVivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Vivani Medical has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. This event is expected to enhance the company's visibility and engagement with potential investors. The participation underscores Vivani's commitment to growth and innovation in the biopharma sector.
Read more →VANI▲ +8.6%on this news
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
Vivani Medical has released a business update along with its financial results for the second quarter of 2024. The article provides insights into the company's performance and strategic direction. However, specific details regarding financial metrics or operational changes are not included in the text provided.
Read more →VANIVivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results Initiation of the NPM-115 clinical program expected in the fourth quarter of 2024 with a first-in-human study evaluating a miniatu
Vivani Medical reported its financial results for Q2 2024, announcing plans to initiate the NPM-115 clinical program for a GLP-1 implant aimed at obesity treatment by Q4 2024. The FDA recently approved the Investigational New Drug Application for NPM-119, reinforcing the potential of Vivani's GLP-1 implant portfolio. Despite these positive developments, the company posted a net loss of $5.3 million, highlighting ongoing financial issues. There was a decrease in cash reserves from $31 million to $26.3 million, raising concerns about future funding.
Read more →VANI▲ +5.6%on this news
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
Vivani Medical has announced updates regarding its clinical development plans for NPM-115, a miniature, long-term GLP-1 obesity implant. The program aims to address obesity through innovative technology. The company's focus on this area reflects a commitment to improving treatment options for patients.
Read more →VANI▲ +5.6%on this newsshared move
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115 Vivani expects to initiate the first clinical study supporting the NPM-1
Vivani Medical, Inc. announced plans to begin clinical studies for its NPM-115 obesity treatment program by the fourth quarter of 2024, pending regulatory approval in Australia. The clinical program will focus on a six-month GLP-1 implant designed for chronic weight management in overweight patients. Positive preclinical data supports the program, and if successful, further studies may explore higher doses. The company's strategic shift to prioritize obesity treatments aligns with market demands and medical needs.
Read more →VANIVivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
Vivani Medical has announced that the FDA has cleared its Investigational New Drug Application for NPM-119, a miniature long-term subdermal GLP-1 drug implant. This decision also lifts the clinical hold previously placed on the product, allowing the company to proceed with its clinical trials. The development is seen as a significant step forward in the company's drug delivery technology.
Read more →VANIVivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant NPM-119 is being studied to address medication non-adherenc
Vivani Medical has announced that the FDA has cleared its Investigational New Drug application and lifted the clinical hold on NPM-119, a miniature subdermal GLP-1 drug implant designed to treat type 2 diabetes. This approval allows the company to initiate LIBERATE-1, a Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of NPM-119. The drug aims to address issues of medication non-adherence, which affects a significant portion of diabetes patients. The upcoming study marks a critical step as Vivani transitions to a clinical-stage company with promising therapeutic options.
Read more →VANIVivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
Vivani Medical has announced the publication of positive data regarding weight loss associated with its OKV-119 miniature GLP-1 implant. This data supports the potential use of the implant in veterinary applications. The long-term nature of the implant may offer significant benefits for weight management in animals.
Read more →VANIVivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
Vivani Medical has released a business update along with its financial results for the first quarter of 2024. The report includes key financial metrics and insights into the company's operations. However, specific details regarding performance or strategic initiatives were not disclosed in the article.
Read more →VANIVivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results Company continues advancing the development of miniature, long-term GLP-1 implants for the treatment of chronic weight management i
Vivani Medical has provided a business update and reported its financial results for the first quarter of 2024. The company is actively developing GLP-1 implants, with NPM-115 showing promising preclinical weight loss results compared to existing treatments. Despite a net loss of $6.0 million for the quarter, Vivani's cash position has improved to support operations through 2025. The anticipated submission of key IND applications continues to progress, indicating a proactive approach to regulatory engagement.
Read more →VANIVivani Medical to Present at TIDES Conference 2024
Vivani Medical is set to present at the TIDES Conference 2024, showcasing their strategic focus on NPM-139, a semaglutide implant. This participation underscores their commitment to innovation in biopharma. The conference will provide a platform for Vivani to highlight their advancements and engage with industry peers.
Read more →VANIVivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Vivani Medical has released a business update alongside its financial results for the fourth quarter and full year of 2023. The report includes key financial metrics and insights into the company's performance over the past year. Further details on specific business developments were not provided in the article.
Read more →VANIVivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Strategic shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight manage
Vivani Medical has shifted its strategic focus to the development of GLP-1 implants for obesity treatment, particularly highlighting its lead asset NPM-115. Recent preclinical results show that NPM-115 has weight loss efficacy comparable to semaglutide. The company secured $15 million in funding to accelerate its development programs and sustain operations through mid-2025. However, Vivani reported a significant increase in net losses and faces risks related to regulatory approvals.
Read more →VANIVivani Medical Appoints Daniel Bradbury to its Board of Directors
Vivani Medical has appointed Daniel Bradbury to its Board of Directors. His extensive experience in the biopharma industry is expected to contribute positively to the company's strategic direction. This appointment follows a series of leadership changes aimed at strengthening the company's governance.
Read more →VANIVivani Medical Appoints Daniel Bradbury to its Board of Directors Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight manage
Vivani Medical has appointed Daniel Bradbury, a veteran in the biopharmaceutical industry, to its Board of Directors. Bradbury's experience includes leading Amylin Pharmaceuticals, where he was instrumental in launching the first once-weekly GLP-1 receptor agonist. This appointment is positioned to enhance Vivani's focus on the development of GLP-1 implants aimed at treating obesity and chronic weight conditions. Vivani's lead programs, NPM-115 and NPM-119, are designed to tackle challenges related to medication adherence in patients with obesity and type 2 diabetes.
Read more →VANI▼ -26.8%on this news· ran to -48% by day 3shared move
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
Vivani Medical, Inc. has announced the pricing of a registered direct offering, aiming to raise $15 million by selling shares of common stock and warrants. The shares will be priced at $3.80 each, with warrants exercisable immediately. While the offering is set to close on March 5, 2024, it is subject to standard closing conditions. The company continues to develop long-term drug implants designed to enhance medication adherence, despite facing a clinical hold from the FDA for one of its drug candidates due to additional information requests.
Read more →VANI▲ +270.3%on this newsshared move
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
Vivani Medical has announced positive preclinical data for its weight loss candidate NPM-115, which shows results comparable to the well-known treatments Ozempic and Wegovy. The company is also shifting its strategy to prioritize its obesity portfolio, introducing NPM-139 as a new candidate similar to Semaglutide. This strategic focus may enhance Vivani's position in the obesity treatment market.
Read more →VANI▲ +270.3%on this newsshared move
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic /Wegovy and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio NPM-115 (
Vivani Medical has announced promising preclinical data for its weight loss implant, NPM-115, which exhibits results comparable to injectable drugs like Ozempic and Wegovy. The company also revealed NPM-139, featuring semaglutide, which may offer a once-yearly dosing option. This strategic shift emphasizes Vivani's focus on obesity treatments, aiming to improve medication adherence through its innovative NanoPortal technology. However, both NPM-115 and NPM-139 require further regulatory approvals, and NPM-119's clinical study is currently on hold pending FDA review.
Read more →VANI▼ -6.3%on this news
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
Vivani Medical has released a business update along with its financial results for the third quarter. The announcement includes insights into the company's current operations and financial performance. Further details on the implications of these results were not provided in the article.
Read more →VANI▼ -6.3%on this newsshared move
Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI
Vivani Medical, Inc. is focusing on developing miniature drug implants to enhance treatment for type 2 diabetes and obesity through its NanoPortal technology. The company is targeting significant market opportunities with its lead products, NPM-119 and NPM-115, set to advance in 2024. However, they face risks related to clinical trial successes, regulatory approvals, and competition within the biopharmaceutical landscape. The estimations for the GLP-1 market show a potential growth, which could favor Vivani’s strategic plans.
Read more →VANIVivani Medical to Present at BIO Investor Forum
Vivani Medical is set to present at the BIO Investor Forum, showcasing their strategic focus on NPM-139, a semaglutide implant. This event represents an opportunity for the company to engage with potential investors and stakeholders. The presentation aims to highlight the significance of their product in the biopharma landscape.
Read more →VANIVivani Medical to Present at the Boulder Peptide Symposium
Vivani Medical is set to present at the Boulder Peptide Symposium, highlighting its commitment to engaging with the scientific community. This event offers an opportunity for the company to showcase its advancements in peptide technology. Participation in such symposiums can foster collaboration and innovation in the biopharma sector.
Read more →VANIVivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
Vivani Medical's subsidiary, Cortigent, is set to present results from the Orion Clinical Study at The Eye and The Chip World Research Congress on Artificial Vision, taking place from October 8-10. This presentation highlights the potential advancements in artificial vision technology. The event is significant for stakeholders in the field of vision restoration.
Read more →VANI▼ -10.7%on this news
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
Vivani Medical has released its financial results for the second quarter of 2023, along with a business update. The report includes key financial metrics and insights into the company's ongoing operations. Further details on the company's performance and future plans are anticipated in subsequent communications.
Read more →VANIVivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
Vivani Medical's subsidiary, Cortigent, has released an update on its 5-year early feasibility study for the Orion® Visual Cortical Prosthesis System. This update highlights the progress made in the study, suggesting potential advancements in visual restoration technology. The findings could have significant implications for individuals with vision impairments.
Read more →VANI▲ +5.7%on this newsshared move
VIVANI MEDICAL, INC. PLAN OF CONVERSION This Plan of Conversion (this "Plan") sets forth certain terms of the conversion of Vivani Medical, Inc. (f/k/a Second Sight Medical Products, Inc.), a California corporation (the
Vivani Medical, Inc. has announced its plan to convert from a California corporation to a Delaware corporation. This decision, approved by both the board of directors and stockholders, is part of a strategic move intended to align the company with Delaware's corporate laws. Upon conversion, all existing shares of California Common Stock will be canceled and converted to shares of Delaware Common Stock, ensuring continuity in operations and governance. The conversion is anticipated to be recognized as a reorganization under U.S. tax codes.
Read more →VANIincluded in Form 8-K filed with the SEC on
Vivani Medical, Inc. has filed a Form 8-K with the SEC, outlining its development activities and potential risks related to its product candidates. The company is focused on innovative drug implants for chronic diseases, particularly targeting Type 2 diabetes with its NPM-119 candidate. Vivani is assessing strategic options for its Orion II project aimed at treating profound blindness. While the company is positioned to achieve multiple milestones, it faces significant uncertainties regarding product development and regulatory approvals.
Read more →VANI▼ -5.3%on this news
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates Emeryville, CA. -- (BUSINESS WIRE)
Medical Reports Third Quarter 2022 Results and Provides Business Updates CA. -- (BUSINESS WIRE) -- Nov. 14, 2022 - Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-term drug implants including lead asset
Read more →VANIMedical, Inc.
Medical, Inc. combination of Nano Precision Medical and Second Sight Medical Products Nasdaq: VANI October 17, 2022 www.vivani.com The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities
Read more →VANIVivani Announces Trading under New Ticker Symbol (Nasdaq: VANI) Emeryville, CA - (BUSINESS NEWSWIRE)
Announces Trading under New Ticker Symbol (Nasdaq: VANI) CA - (BUSINESS NEWSWIRE) - August 31, 2022 - Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ: VANI) (the "Company" or "Vivani") announced that trading of the Company's common stock on The Nasdaq Capita
Read more →VANISecond Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting Second Sight to change its name to V
Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting Sight to change its name to Vivani Medical, Inc. Los Angeles, CA - (BUSINESS NEWSWIRE) - July 29, 2022 - Second Sight Med
Read more →VANISecond Sight Medical Products Announces Year Four NIH Funding of its Orion Study Grant proceeds support an ongoing early feasibility study of Orion Los Angeles, CA - (BUSINESS NEWSWIRE)
Sight Medical Products Announces Year Four NIH Funding of its Orion Study proceeds support an ongoing early feasibility study of Orion Los Angeles, CA - (BUSINESS NEWSWIRE) - July 18, 2022 - Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"),
Read more →VANISecond Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company Nano Precision Medical's lead program (NPM-119) is a tiny subdermal implant of a GLP-1 rece
Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company ANGELES and EMERYVILLE, CA, Feb. 7, 2022 - Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight") and Nano Precision Medical,
Read more →VANISecond Sight Medical Products Announces Proposed Public Offering of Common Stock Los Angeles, CA - (BUSINESS NEWSWIRE)
Sight Medical Products Announces Proposed Public Offering of Common Stock Angeles, CA - (BUSINESS NEWSWIRE) - June 22, 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company") a leading developer of implantable visual prosthetics that are inte
Read more →VANISecond Sight Medical Products Announces Closing of Public Offering Los Angeles, CA - (BUSINESS NEWSWIRE) June 25 , 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "C
Sight Medical Products Announces Closing of Public Offering Angeles, CA - (BUSINESS NEWSWIRE) June 25 , 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a leading developer of implantable visual prosthetics that are intended to create
Read more →VANISecond Sight Medical Products Announces Results of its 2021 Annual Meeting Los Angeles, CA - (BUSINESS NEWSWIRE)
Second Sight Medical Products Announces Results of its Los Angeles, CA - (BUSINESS NEWSWIRE) - June 1, 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create a
Read more →VANISecond Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors Los Angeles, CA - (BUSINESS NEWSWIRE)
Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors Los Angeles, CA - (BUSINESS NEWSWIRE) - April 6, 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer and marketer of implant
Read more →VANISecond Sight Medical Products Names Scott Dunbar Acting CEO
Second Sight Medical Products Names Scott Dunbar Acting CEO Los Angeles, CA - (BUSINESS NEWSWIRE) - April 1, 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer and marketer of implantable visual prosthetics that are i
Read more →VANISecond Sight Medical Products Announces Closing of $27.9 Million Private Placement of Common Stock
Second Sight Medical Products Announces Closing of $27.9 Million Private Placement of Common Stock Los Angeles, CA - (BUSINESS NEWSWIRE) -- March 26, 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer and marketer of
Read more →VANISecond Sight Medical Products Announces $27.9 Million Private Placement of Common Stock
Second Sight Medical Products Announces $27.9 Million Private Placement of Common Stock LOS ANGELES, CALIFORNIA, March 24, 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES), (the "Company" or "Second Sight"), a leading developer and marketer of implantable visual prosthe
Read more →VANISecond Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System Los Angeles - (Business Wire)
Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System Los Angeles - (Business Wire) - March 5, 2021, Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to
Read more →VANISecond Sight Medical Products Matthew J. Pfeffer Chief Executive Officer publicrelations@secondsight.com Page 6 /4
Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market Paris, France and Los Angeles, Calif., January 06, 2021 - 06.00 CET - Pixium Vision (Euronext Growth Paris - FR0011950641), a bioelectronics co
Read more →VANIInvestor Relations In-Site Communications, Inc. Lisa Wilson, President T: 212-452-2793 E: lwilson@insitecony.com
Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion Cortical Visual Prosthesis at UCLA September 22, 2020 08:00 AM Eastern Daylight Time LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products Inc. (NASDAQ: EYES), a developer,
Read more →VANISecond Sight Medical Products Inc. Announces Closing of Public Offering of Common Stock
Second Sight Medical Products Inc. Announces Closing of Public Offering of Common Stock LOS ANGELES-May 5, 2020 -- Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificia
Read more →VANISecond Sight Medical Products Announces Pricing of Public Offering of Common Stock
Second Sight Medical Products Announces Pricing of Public Offering of Common Stock LOS ANGELES-April 30, 2020-Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial for
Read more →VANISecond Sight Medical Products Provides Business Update LOS ANGELES
Second Sight Medical Products Provides Business Update LOS ANGELES -- April 28, 2020 -- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an a
Read more →VANISecond Sight Announces Employee Layoffs, Intent to Wind Down Operations and Appointment of Matthew Pfeffer as Acting CEO Los Angeles
Second Sight Announces Employee Layoffs, Intent to Wind Down Operations and Appointment of Matthew Pfeffer as Acting CEO Los Angeles - March 30, 2020 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of
Read more →VANISecond Sight Reports Fourth Quarter and Full Year 2019 Financial Results -- Received CE Mark Certification and U.S. Food and Drug Administration conditional approval for Argus 2s, next-generation we
Second Sight Reports Fourth Quarter and Full Year 2019 Financial Results -- Received CE Mark Certification and U.S. Food and Drug Administration conditional approval for Argus 2s, next-generation wearables - Los Angeles, CA - March 19, 2020 - Second Sight Medical Products, Inc.
Read more →VANISecond Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEO - Mr. McGuire to Remain on Second Sight's Board of Directors - - Company continue
Second Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEO Los Angeles, CA - March 12, 2020 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of
Read more →VANIEx. 99.1 FOR IMMEDIATE RELEASE Second Sight Reports Third Quarter 2019 Financial Results -- Reached agreement with FDA regard ing the primary efficacy endpoint for the Orion pivotal trial
Second Sight Reports Third Quarter 2019 Financial Results -- Reached agreement with FDA regarding the primary efficacy endpoint for the Orion pivotal trial -- LOS ANGELES - November 14, 2019 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"),
Read more →VANIeyes-ex991_6.pptx.htm Second Sight Medical Products, Inc. (NASDAQ: EYES) Discover Life in a New Light 2019 Wells Fargo Healthcare Conference
Second Sight Medical Products, Inc. (NASDAQ: EYES) Discover Life in a New Light 2019 Wells Fargo Healthcare Conference September 4, 2019 Ex 99.1 The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of th
Read more →VANISecond Sight Reports Second Quarter 2019 Financial Results -- R&D and Clinical Programs for Orion Visual Cortical Prosthesis System on Track
Second Sight Reports Second Quarter 2019 Financial Results -- R&D and Clinical Programs for Orion Visual Cortical Prosthesis System on Track -- LOS ANGELES - August 6, 2019 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manu
Read more →VANIResearchers Present Latest Positive Results of Second Sight's Orion Visual Cortical Prosthesis Feasibility Study Study Investigators from UCLA and Baylor Provide Latest Study Update at the World Soc
Researchers Present Latest Positive Results of Second Sight's Orion Visual Cortical Prosthesis Feasibility Study Study Investigators from UCLA and Baylor Provide Latest Study Update at the World Society for Stereotactic and Functional Neurosurgery Annual Meeting LOS ANGELES and
Read more →VANIeyes-ex991_6.pptx.htm Second Sight Medical Products, Inc. (NASDAQ: EYES) Discover Life in a New Light B. Riley FBR Investor Conference
Second Sight Medical Products, Inc. (NASDAQ: EYES) Discover Life in a New Light B. Riley FBR Investor Conference May 23, 2019 Ex 99.1 This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 2
Read more →VANISecond Sight Reports First Quarter 2019 Financial Results -- Company to Accelerate Development of Orion Visual Cortical Prosthesis System
Second Sight Reports First Quarter 2019 Financial Results -- Company to Accelerate Development of Orion Visual Cortical Prosthesis System -- LOS ANGELES - May 15, 2019 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufactu
Read more →VANISecond Sight to Accelerate Development of Orion Visual Cortical Prosthesis System -- Positive Results of Early Feasibility Study and Significant Market Potential Drive Refined Strategy -- -- Company
Second Sight to Accelerate Development of Orion Visual Cortical Prosthesis System -- Positive Results of Early Feasibility Study and Significant Market Potential Drive Refined Strategy -- -- Company to Provide Continued Support for Existing Argus II Users Worldwide -- LOS ANGE
Read more →VANIo Observations from rehabilitation sessions include that subjects are able to use Orion to visually detect parked cars, identify the direction of motion of a person walking by, and visually order small objects by size &#
Second Sight Medical Products, Inc. Presents Positive Interim Results at the Fifth Annual BRAIN Initiative Investigators Meeting -- Presentation to Provide Update of Early Feasibility Study of the Orion Visual Prosthesis System -- Los Angeles, CA - April 11, 2019 - Second Sigh
Read more →VANISecond Sight Reports Fourth Quarter and Full Year 2018 Financial Results Los Angeles, CA
Second Sight Reports Fourth Quarter and Full Year 2018 Financial Results Los Angeles, CA - March 13, 2019 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are int
Read more →VANISecond Sight Medical Products, Inc. Announces Completion of Rights Offering Expiration date of all outstanding warrants listed for trading under the "EYESW" symbol is extended to 5:00 p.m. New York
Second Sight Medical Products, Inc. Announces Completion of Expiration date of all outstanding warrants listed for trading under the "EYESW" symbol is extended to 5:00 p.m. New York time on March 14, 2024 Sylmar, CA - February 21, 2019 - Second Sight Medical Products, Inc. (NAS
Read more →VANINASDAQ: EYES Enriching the Lives of the Blind May 2018 NASDAQ: EYES NASDAQ: EYES Forward Looking Statements This press release contains forward - looking statements within the meaning of Section 27A of the Securities Act
NASDAQ: EYES Enriching the Lives of the Blind May 2018 NASDAQ: EYES NASDAQ: EYES Forward Looking Statements This press release contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exc
Read more →VANISecond Sight Reports First Quarter 2018 Financial Results -Orion Feasibility Study on Track with Encouraging Early Results and Four of Five Subjects Implanted - - Completed Private Placement of $10
Reports First Quarter 2018 Financial Results -Orion Feasibility Study on Track with Encouraging Early Results and Four of Five Subjects Implanted - - Completed Private Placement of $10 Los Angeles, CA - May 10, 2018 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Seco
Read more →VANISecond Sight Completes $10 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors Los Angeles, CA
Sight Completes $10 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors Angeles, CA - May 7, 2018 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of impl
Read more →VANISecond Sight Announces Dr. Robert Greenberg's Resignation from Board of Directors and as an Officer of the Company Los Angeles, CA
Second Sight Announces Dr. Robert Greenberg's Resignation from Board of Directors and as an Officer of the Company Los Angeles, CA - April 9, 2018 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of
Read more →VANISecond Sight Appoints John T. Blake Chief Financial Officer Sylmar, CA
Sight Appoints John T. Blake Chief Financial Officer CA - March 22, 2018 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial f
Read more →VANISecond Sight Appoints Gregg Williams as Chairman of the Board of Directors Sylmar, CA
Second Sight Appoints Gregg Williams as Chairman of the Board of Directors Sylmar, CA - March 16, 2018 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are int
Read more →VANISecond Sight Reports Fourth Quarter and Full Year 2017 Financial Results -- Year-over-year net sales in 2017 double to $8 million, driven by record implant volume -- SYLMAR, Calif.--(BUSINESS WIRE)
Sight Reports Fourth Quarter and Full Year 2017 Financial Results Year-over-year net sales in 2017 double to $8 million, driven by record implant volume -- Calif.--(BUSINESS WIRE)--Mar. 7, 2018-- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Compan
Read more →VANINASDAQ: EYES Enriching the Lives of the Blind March 2018 NASDAQ: EYES NASDAQ: EYES Forward Looking Statements 2 This press release contains forward - looking statements within the meaning of Section 27A of the Securities
EYES Enriching the Lives of the Blind March 2018 NASDAQ: EYES EYES Forward Looking Statements 2 This press release contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and E
Read more →VANISecond Sight Announces Latest Expansion of Medicare Coverage for Argus II Retinal Prosthesis System -- Argus II Covered in Majority of Medicare Administrative Contractor Jurisdictions Across 31 States -- SYLMAR, Calif.--
Second Sight Announces Latest Expansion of Medicare Coverage for Argus II Retinal Prosthesis System -- Argus II Covered in Majority of Medicare Administrative Contractor Jurisdictions Across 31 States -- SYLMAR, Calif.--(BUSINESS WIRE)--Mar. 6, 2018-- Second Sight Medical Pr
Read more →VANISecond Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical Implant SYLMAR, Calif.--(BUSINESS WIRE)
Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical Implant Calif.--(BUSINESS WIRE)--Feb. 5, 2018-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufactur
Read more →VANISecond Sight Announces Market Entry into Iran with First Two Implants of Argus II Retinal Prosthesis System - Marks Continued Global Expansion of Argus II for Individuals Blinded by Retinitis Pigmentosa - SYLMAR, Calif.-
Sight Announces Market Entry into Iran with First Two Implants of Argus II Retinal Prosthesis System Marks Continued Global Expansion of Argus II for Individuals Blinded by Retinitis Pigmentosa - SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ: EY
Read more →VANISecond Sight Receives FDA Expedited Access Pathway Designation for the Orion Cortical Visual Prosthesis System -- Allows patients to have more timely access to medical devices by expediting their development, assessment,
Second Sight Receives FDA Expedited Access Pathway Designation for the Orion Cortical Visual Prosthesis System to have more timely access to medical devices by expediting their development, assessment, and review -- SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Produ
Read more →VANIOntario Health Technology Advisory Committee Recommends Public Funding for Second Sight's Argus II Retinal Prosthesis System SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ( Second Si
Ontario Health Technology Advisory Committee Recommends Public Funding for Second Sight's Argus II Retinal Prosthesis System SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and ma
Read more →VANISecond Sight Receives Full FDA Approval to Begin First Orion Human Clinical Study --Second Sight has completed additional device testing and addressed outstanding questions previously requested by the FDA-- SYLMAR, Calif
Sight Receives Full FDA Approval to Begin First Orion Human Clinical Study Sight has completed additional device testing and addressed outstanding questions previously requested by the FDA-- Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Si
Read more →VANISecond Sight Announces Final Medicare Hospital Outpatient Payment Rate for 2018 for the Argus II Retinal Prosthesis System SYLMAR, Calif.--(BUSINESS WIRE)- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight
Sight Announces Final Medicare Hospital Outpatient Payment Rate for 2018 for the Argus II Retinal Prosthesis System Calif.--(BUSINESS WIRE)- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight"), a developer, manufacturer and marketer of implantable visual prosthet
Read more →VANISecond Sight Reports Third Quarter 2017 Financial Results Sylmar, CA
Sight Reports Third Quarter 2017 Financial Results CA, November 2, 2017 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial fo
Read more →VANISecond Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ( Second Sight or the Company ), a developer, m
Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide u
Read more →VANISecond Sight Announces Market Entry into Russia with First Implant of Argus II Retinal Prosthesis System - Marks Continued Global Expansion of Argus II for Individuals Blinded by Retinitis Pigmentosa - SYLMAR, Calif.--(B
Sight Announces Market Entry into Russia with First Implant of Argus II Retinal Prosthesis System Global Expansion of Argus II for Individuals Blinded by Retinitis Pigmentosa - SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight"
Read more →VANISecond Sight Announces Market Entry into South Korea with Two
Second Sight Announces Market Entry into South Korea with Two Implants and Performs Second Implant in Taiwan of Argus II Retinal Prosthesis System -Marks Continued Expansion of Argus II SYLMAR, Calif.-(BUSINESS WIRE)- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second
Read more →VANISecond Sight Announces Expansion of Medicare Coverage for Argus II Retinal Prosthesis System to 11 Additional States and the District of Columbia -- Argus II Can Now Be Covered in Seven of 12 Medicare Administrative Cont
Second Sight Announces Expansion of Medicare Coverage for Argus II Retinal Prosthesis System to 11 Additional States and the District of Columbia -- Argus II Can Now Be Covered in Seven of 12 Medicare Administrative Contractor Jurisdictions, representing a total of 28 states,
Read more →VANINASDAQ: EYES A Better Way of Life for Patients May 2017 NASDAQ: EYES
NASDAQ: EYES A Better Way of Life for Patients May 2017 NASDAQ: EYES NASDAQ: EYES Forward Looking Statements This presentation contains certain forward - looking information about Second Sight that is intended to be covered by the safe harbor for "forward - looking statements" p
Read more →VANISecond Sight Reports First Quarter 2017 Financial Results SYLMAR, Calif.- (BUSINESS WIRE) - Second Sight Medical Products, Inc. (NASDAQ:EYES) ( Second Sight or the Company ), a developer, manufacturer and marketer of imp
Reports First Quarter 2017 Financial Results SYLMAR, Calif.- (BUSINESS WIRE) - Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind p
Read more →VANISecond Sight Medical Products,
Second Sight Medical Products, Announces Warrants Approved for Listing on Nasdaq With Trading Scheduled to Commence March 29 under Symbol "EYESW" Business Wire March 27, SYLMAR, Calif.-(BUSINESS WIRE)- Second Sight Medical Products, Inc. (EYES), (the "Company"), a develop
Read more →VANISecond Sight Reports Fourth Quarter and
Second Sight Reports Fourth Quarter and Year End 2016 Financial Results Sylmar, CA, March 9, 2017 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some u
Read more →VANISecond Sight Medical Products, Inc. Announces Completion of Oversubscribed Rights Offering Sylmar, CA
Second Sight Medical Products, Inc. Announces Completion of Oversubscribed Sylmar, CA - March 9, 2017 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that provide
Read more →VANISecond Sight Appoints David Jacques as Vice President of Research and Development SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ( Second Sight or the Company ), a developer, manufact
Second Sight Appoints David Jacques as Vice President of Research and Development SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics tha
Read more →VANIUK Government Announces Funding for Second Sight's Argus II "Bionic Eye"
UK Government Announces Funding for Second Sight's Argus II "Bionic Eye" December 22, 2016 06:00 AM Eastern Standard Time SYLMAR, Calif. & LAUSANNE, Switzerland-(BUSINESS WIRE)-Second Sight Medical Products, Inc. (Nasdaq:EYES) ("Second Sight"), a developer, manufacturer and m
Read more →VANISecond Sight Medical Products, Inc.
INDEPENDENT ACCOUNTANTS' ON APPLYING AGREED-UPON To the Board of Directors Second Sight Medical Products, Inc. We have performed the procedures enumerated below, which were agreed to by Second Sight Medical Products, Inc. (the Company), solely to assist you with respect to t
Read more →VANISecond Sight Reports Third Quarter 2016 Financial Results SYLMAR, Calif.-(BUSINESS WIRE)- Second Sight Medical Products, Inc. (NASDAQ:EYES) ( Second Sight or the Company ), a developer, manufacturer and marketer of impla
Second Sight Reports Third Quarter 2016 Financial Results SYLMAR, Calif.-(BUSINESS WIRE)- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide a form of useful
Read more →VANISecond Sight Announces Final CMS Hospital Outpatient Payment Rate for 2017 and Two New CPT Codes for Programming the Argus II Retinal Prosthesis System SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc
Sight Announces Final CMS Hospital Outpatient Payment Rate for 2017 and Two New CPT Codes for Programming the Argus II Retinal Prosthesis System Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight"), a developer, manufacturer and marketer
Read more →VANISecond Sight Announces Successful Implantation and Activation of Wireless Visual Cortical Stimulator in First Human Subject Provides Proof of Concept for the Ongoing Development of the Orion I Visual Cortical Prosthesis
Sight Announces Successful Implantation and Activation of Wireless Visual Cortical Stimulator in First Human Subject Proof of Concept for the Ongoing Development of the Orion I Visual Cortical Prosthesis Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYE
Read more →VANISecond Sight Reports Second Quarter 2016 Financial Results Sylmar, CA
Second Sight Reports Second Quarter 2016 Sylmar, CA, July 28, 2016 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients,
Read more →VANISecond Sight Announces Positive Five-Year Data from Argus II Retinal Prosthesis System Study Results Published in Ophthalmology Show Safety and Sustained Improvement in Visual Performance for Blind Patients SYLMAR, Calif
Second Sight Announces Positive Five-Year Data from Argus II Retinal Prosthesis System Study Results Published in Ophthalmology Show Safety and Sustained Improvement in Visual Performance for Blind Patients SYLMAR, Calif.-(BUSINESS WIRE)- Second Sight Medical Products, Inc.
Read more →VANISecond Sight Medical Products, Inc. Announces Completion of Oversubscribed Rights Offering
Sight Medical Products, Inc. Announces Completion of Oversubscribed Rights Offering Sylmar California--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prostheti
Read more →VANISecond Sight Reports First Quarter 2016 Financial Results Sylmar, CA
Sight Reports First Quarter 2016 Financial Results Sylmar, CA, April 28, 2016 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind
Read more →VANISecond Sight Appoints Steven D. Okland Jr. as Commercial Vice President, U.S. and Canada Sylmar, CA.
Second Sight Appoints Steven D. Okland Jr. as Commercial Vice President, U.S. and Canada Sylmar, CA.-March 24, 2016- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics
Read more →VANISecond Sight Reports Fourth Quarter and Year End 2015 Financial Results Sylmar, CA
Second Sight Reports Fourth Quarter and Year End 2015 Financial Results Sylmar, CA, March 3, 2016 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some u
Read more →VANINASDAQ: EYES Investor Presentation 2016 NASDAQ: EYES NASDAQ: EYES Forward Looking Statements This presentation contains certain forward - looking information about Second Sight that is intended to be covered by the safe
NASDAQ: EYES Investor Presentation 2016 NASDAQ: EYES NASDAQ: EYES Forward Looking Statements This presentation contains certain forward - looking information about Second Sight that is intended to be covered by the safe harbor for "forward - looking statements" provided by the P
Read more →VANISecond Sight Announces Publication of Positive Results in 3-Year FLORA Study of the Argus II SYLMAR, Calif.-(BUSINESS WIRE)- Second Sight Medical Products, Inc. ( Second Sight or the Company ) (Nasdaq: EYES), a developer
Sight Announces Publication of Positive Results in 3-Year FLORA Study of the Argus II SYLMAR, Calif.-(BUSINESS WIRE)- Second Sight Medical Products, Inc. ("Second Sight" or "the Company") (Nasdaq: EYES), a developer, manufacturer and marketer of implantable visual prosthetics
Read more →VANISecond Sight Provides Business Update and Key Performance Metrics for Full Year 2015 Record Level of Argus II Implants in Fourth Quarter and 2015; Poised for Continued Growth in 2016 Sylmar, CA
Sight Provides Business Update and Key Performance Metrics for Full Year 2015 Level of Argus II Implants in Fourth Quarter and 2015; Poised for Continued Growth in 2016 CA, January 11, 2016 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"),
Read more →VANISecond Sight Medical Products, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Sylmar, CA
Sight Medical Products, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CA, December 4, 2015 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to p
Read more →VANISecond Sight Reports Third Quarter 2015 Financial Results Sylmar, CA
Sight Reports Third Quarter 2015 Financial Results CA, October 29, 2015 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patien
Read more →VANISecond Sight Reports Second Quarter 2015 Financial Results Sylmar, CA
Sight Reports Second Quarter 2015 Financial Results Sylmar, CA, August 04, 2015 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to bli
Read more →VANISecond Sight Announces First Age-Related Macular Degeneration Patient Receives the Argus II Retinal Prosthesis System as Part of Groundbreaking Study Five Patients to be Implanted with the Argus II to Evaluate the Feasib
Sight Announces First Age-Related Macular Degeneration Patient Receives the Argus II Retinal Prosthesis System as Part of Groundbreaking Five Patients to be Implanted with the Argus II to Evaluate the Feasibility of the Device in Patients with Dry Age-Related Macular Degenerati
Read more →VANISecond Sight Appoints Will McGuire as
Second Sight Appoints Will McGuire as Dr. Robert Greenberg appointed Chairman of the Board of Directors Dr. Alfred Mann assumes role of Chairman Sylmar, CA, June 25, 2015 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, man
Read more →VANISecond Sight Appoints Matthew J. Pfeffer to Its Board of Directors Sylmar, CA
Sight Appoints Matthew J. Pfeffer to Its Board of Directors CA, June 3, 2015 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that provide functional vision to blind
Read more →VANIAnnounces Exclusive Agreement with Gulf Medical Company to Distribute the Argus II Retinal Prosthesis System in Saudi Arabia
Announces Exclusive Agreement with Gulf Medical Company to Distribute the Argus II Retinal Prosthesis System in Saudi Arabia Sylmar, California- May 7, 2015 - Second Sight Medical Products, Inc. ("Second Sight" or "the Company") (NASDAQ: EYES), a developer, manufacturer and mar
Read more →VANISecond Sight Reports First Quarter 2015 Financial Results Sylmar, CA
Sight Reports First Quarter 2015 Financial Results Sylmar, CA, May 13, 2015 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind pa
Read more →VANISecond Sight Announces Senior Management Appointments in Commercialization and Manufacturing Sylmar, CA
Sight Announces Senior Management Appointments in Commercialization and Manufacturing Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to restore functional vision to
Read more →VANISecond Sight Reports Fourth Quarter and Year End 2014 Financial Results and Provides Business Update Sylmar, CA
Second Sight Reports Fourth Quarter and Year End 2014 Financial Results and Provides Business Update Sylmar, CA, March 11, 2015 - Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a leading developer, manufacturer and marketer of implantabl
Read more →VANISecond Sight Receives Highest Priority Reimbursement for Argus II in Germany Sylmar, CA
Second Sight Receives Highest Priority Reimbursement for Argus II in Germany CA, February 3, 2015 - Second Sight Medical Products, Inc. (Nasdaq: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide functi
Read more →VANINasdaq : EYES Investor Presentation NASDAQ: EYES January 2015 Nasdaq : EYES Forward Looking Statements This presentation contains certain forward - looking information about Second Sight that is intended to be covered by
Nasdaq : EYES Investor Presentation NASDAQ: EYES January 2015 Nasdaq : EYES Forward Looking Statements This presentation contains certain forward - looking information about Second Sight that is intended to be covered by the safe harbor for "forward - looking statements" provide
Read more →Competitive Position
How VANI ranks across every disease it competes inCompetitive Position is a premium feature
See how VANI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial